Corvus Pharmaceuticals Files 2024 10-K
Ticker: CRVS · Form: 10-K · Filed: Mar 25, 2025 · CIK: 1626971
| Field | Detail |
|---|---|
| Company | Corvus Pharmaceuticals, Inc. (CRVS) |
| Form Type | 10-K |
| Filed Date | Mar 25, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, pharmaceuticals, licensing
TL;DR
CRVS 2024 10-K filed: $61M assets, $48M liabilities. Details on R&D and licenses.
AI Summary
Corvus Pharmaceuticals, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, located at 863 Mitten Road, Suite 102, Burlingame, CA 94010, reported financial data including $60,985,165 in assets and $48,025,274 in liabilities. The filing covers their operations in pharmaceutical preparations and includes details on license agreements with entities like Vernalis R&D Limited and Monash License.
Why It Matters
This filing provides a comprehensive overview of Corvus Pharmaceuticals' financial health and operational status for the past fiscal year, crucial for investors and stakeholders to assess the company's performance and future prospects.
Risk Assessment
Risk Level: medium — The company operates in the highly regulated and competitive pharmaceutical industry, which inherently carries significant risks related to drug development, clinical trials, and market approval.
Key Numbers
- $60.99B — Total Assets (As of December 31, 2024)
- $48.03B — Total Liabilities (As of December 31, 2024)
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
Key Players & Entities
- Corvus Pharmaceuticals, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 863 Mitten Road, Suite 102, Burlingame, CA 94010 (address) — Company business and mail address
- $60,985,165 (dollar_amount) — Total assets reported
- $48,025,274 (dollar_amount) — Total liabilities reported
- Vernalis R&D Limited (company) — Party to a license agreement
- Monash License (company) — Party to a license agreement
FAQ
What were Corvus Pharmaceuticals' total assets and liabilities as of December 31, 2024?
As of December 31, 2024, Corvus Pharmaceuticals reported total assets of $60,985,165 and total liabilities of $48,025,274.
What is the company's primary business sector?
Corvus Pharmaceuticals, Inc. operates in the Pharmaceutical Preparations sector, SIC code 2834.
What are some of the key license agreements mentioned in the filing?
The filing mentions license agreements with Vernalis R&D Limited and Monash License, with terms relevant to the 2024 fiscal year.
Where is Corvus Pharmaceuticals, Inc. located?
The company's business and mailing address is 863 Mitten Road, Suite 102, Burlingame, CA 94010.
What is the filing date and the period it covers?
This 10-K filing was made on March 25, 2025, and it covers the fiscal year ending December 31, 2024.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 25, 2025 regarding Corvus Pharmaceuticals, Inc. (CRVS).